UNSPSC 51313417: Betahistine mesilate

This classification denotes a vasodilating agent with the molecular formula C8H12N2.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X1L0E3R43Y, chemically known as 2-pyridineethanamine, n-methyl-, dimethanesulfonate but more generally known as betahistine mesilate, which bears US NIH Compound Identifier 198334. The base compound, Betahistine, most often comes in base, dihydrochloride, hydrochloride, and mesylate forms.

European Medicines Agency schedules Betahistine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00773MIG. Most nations, for tariff and trade purposes, schedule betahistine mesilate under HS 29333999 and SITC 51574. As of Q4 2014, BETAHISTINE MESILATE remains US FDA's Preferred Term for this commodity. SMILES: CNCCC1CCCCN1.CS(=O)(=O)O.CS(=O)(=O)O.

UNSPSC 51313417 Betahistine mesilate is a Commodity code that in practice sees minimal direct state and local procurement activity matching its specific pharmaceutical scope. The recent opportunities posted under this code involve naloxone, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products—none of which represent betahistine mesilate procurement. State and local health agencies, pharmacy benefit programs, and cooperative purchasing alliances are the primary issuing bodies active in pharmaceutical procurement, but the alignment between the code's nominal scope and what is actually being solicited is poor.

The geographic spread of recent activity spans Florida (Seminole County), Texas (HHS Commission), and Minnesota (MMCAP, with participation from Oregon), though these opportunities do not constitute betahistine mesilate demand. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking naloxone and drug deactivation systems with a July 26, 2026, response deadline. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription capabilities. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with a March 26, 2026, proposal deadline and July 1, 2026, contract effectiveness. The code shows little relevant recent activity and exhibits a significant mismatch between its stated scope and the pharmaceutical products state and local governments are actively procuring.